News
Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Oct 6, 2021BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled "CSF biomarker...
- Oct 4, 2021
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that Stacy Lindborg, Ph.D., Executive Vice President and...
- Oct 1, 2021Presentation to take place at 10:45 a.m. ET (4:45 p.m. CEST) on October 14, 2021
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled "Phase 2 Safety and...
- Aug 5, 2021Continuing to assess regulatory strategy for advancing NurOwn® towards potential approval in ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the first quarter ended June 30,...
- Jul 27, 2021GMP certification of three state-of-the-art cleanrooms more than doubles the Company's manufacturing capacity for NurOwn® in Israel
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that is has received Good Manufacturing Practice (GMP)...
- Jul 26, 2021
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update...
- Jun 15, 2021
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the grant and/or allowance of a series of...
- May 25, 2021Superior clinical and biomarker outcomes demonstrated with NurOwn exosomes compared to MSC exosomes in Preclinical ARDS Model
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "Molecular...
- Apr 26, 2021- Positive Phase 2 data demonstrate the potential of NurOwn® as a treatment for progressive MS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the first quarter ended March 31,...
- Apr 19, 2021
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update...